Verantos

We made the Inc 5000 list for the third year in a row and are the only real-world evidence company on the 2024 list! Congratulations to the Verantos team who have really advanced the mission of high-validity RWE.

PALO ALTO, Calif., Aug. 1, 2024 /PRNewswire/ -- Verantos, the global leader in high-validity real-world evidence at scale, today announced that Dr. Adam Cheifetz, M.D. of Beth Israel Deaconess Medical Center, and Gil Melmed, M.D. of Cedars-Sinai Medicine, have joined its advisory panel for inflammatory bowel disease (IBD). As senior faculty and experts, they will provide expert input on observational research powered by Verantos' Inflammatory Bowel Disease Pragmatic Registry.

There is a clear emphasis on validation throughout this final guidance document. We look forward to sharing our thoughts with you over the coming weeks.

We’re hiring at Verantos! Actively looking for MLOps Engineer and Data QA candidates for our Pune location. Quick Links: 📌 View Job Posting (https://lnkd.in/gnHTxtWV) 📘 Insightful Article by our CEO, Dan Riskin (https://lnkd.in/dfSyVJaQ) 🏆 Verantos on the 2023 Inc5000 List (https://lnkd.in/duK2_btb) Apply Now! Click on the job posting link above, and let’s start a conversation about the potential of working together. Feel free to tag someone who could be our next tech superstar! #Hiring #healthcare #TechJobs #MLOps #DataQA #JoinOurTeam #worklifebalance #respectatworkplace #jobs

PALO ALTO, Calif. , July 10, 2024 /PRNewswire/ -- Verantos, the global leader in high-validity real-world evidence at scale, today announced the launch of its Alzheimer's Disease Pragmatic Registry, which provides rich and reliable data on patients with Alzheimer's disease and related conditions to life sciences organizations.

Drop by our poster session or visit our booth at #ISPORAnnual next week. We're near the entrance and difficult to miss. We'll be happy to discuss how accuracy, completeness, and traceability of your RWD affect the measurement of health outcomes and resource utilization. And not just in migraine.

PALO ALTO, Calif., April 30, 2024 /PRNewswire/ -- Verantos, the global leader in high-validity real-world evidence at scale, today announced the launch of its Inflammatory Bowel Disease Pragmatic Registry, which provides rich and reliable data on ulcerative colitis and Crohn's disease patients, including specific subgroups to life sciences organizations. A pragmatic registry is a condition-specific, high-quality data set generated using artificial intelligence on routinely collected real-world data. By combining unstructured and structured data from electronic health records with linkage to claims and mortality data, Inflammatory Bowel Disease Pragmatic Registry offers an unparalleled view into disease severity, treatments, symptom control, resource utilization, and clinical outcomes variables.

An important study published by Mount Sinai Health System in the New England Journal of Medicine's AI journal found that large language models perform poorly on medical coding tasks - finding the correct codes from clinical notes. In particular, they lack the specificity required for reimbursement. The study did not evaluate LLM performance on sensitivity, which likely will be high. The study tested models from OpenAI, Google, and Meta. This shows both benefits and drawbacks of LLM-driven approaches towards medical coding, risk adjustment, and quality measures - LLMs are likely to be productive partners in these difficult use cases, but are not precise enough to be the adjudicators or final reviewers.

Part of Verantos' advantage over other RWE companies is our "deep phenotyping" capability — an application of AI to the entire patient record, including unstructured EHR data — which enables life sciences organizations to identify patient subgroups, or phenotypes, with a level of reliability unmatched in the industry. We were able to develop this industry-leading capability with support from The National Institutes of Health National Center for Advancing Translational Sciences (NCATS). Read more at https://go.nih.gov/uJE289g #NCATSsbir

What if #AI had the power to shape the future of personalized treatment? An #NCATSsbir grantee is using AI to study electronic health records to ultimately predict how diseases and different treatments affect patients. See how this innovative work could transform the way doctors make treatment decisions: https://go.nih.gov/uJE289g